2020

• patent2020/12/28

  Korean Intellectual Property Office Granted AskAt a Salt & Crystal Forms Patent of COX-2 Inhibitor (AAT-076)

  AskAt Inc. announced today that AskAt received a notice of allowance dated December 21, 2020 from the Korean Intellectual Property Office in connection with the Application No. 10-2015-7019802, a salt and crystal forms patent for the company’s COX-2 inhibitor (AAT-076).

• patent2020/12/03

  European Patent Office Approves Formulation Patent for AskAt’s COX-2 Inhibitor (AAT-076)

  AskAt Inc. announced today that AskAt received the decision to grant a European patent dated November 17, 2020 from the European Patent Office (EPO) in connection with the Application No. 12841913.2, a formulation patent for the company’s COX-2 inhibitor (AAT-076).

• patent2020/11/13

  USPTO Grants Expansion of AskAt’s EP4 Antagonist Cancer Use Patent

  AskAt Inc. (AskAt) received a Notice of Allowance dated November 3, 2020 from the United States Patent and Trademark Office (USPTO) in connection with Application No.16/803,163, a use patent for AskAt's EP4 antagonist (grapiprant, AAT-007) in the treatment of melanoma, leukemia, lymphoma, and liver cancer. AskAt has previously received an allowance for the use of grapiprant in the treatment of epithelial cancer and several cancer types.
  

• patent2020/11/11

  Ocular Disease Use Patent for COX-2 Inhibitor (AAT-076) Approved in Canada

  AskAt Inc. announced today that AskAt received a notice of allowance dated October 23, 2020 from the Canadian Intellectual Property Office (CIPO) in connection with the Application No. 2,907,783, a use patent of COX-2 inhibitor (AAT-076) for ocular diseases.
  

• business2020/10/08

  GALLIPRANT® Enters Dog Osteoarthritis Pain Market in Japan

  Elanco Japan K.K. (Tokyo, Japan), a division of Elanco Animal Health Inc.(Indiana, USA),today announced the launch of GALLIPRANT®(generic name: grapiprant) in 20 mg and 60 mg tablets for the control of pain and inflammation associated with osteoarthritis in dogs in Japan.

• patent2020/10/07

  Canada Issues Approval for AskAt’s EP4 Antagonist Patent for Autoimmune Disease Use

  AskAt received a Notice of Allowance from the Canadian Intellectual Property Office (CIPO) dated September 14, 2020 in connection with Application No. 3,009,937, a use patent for its EP4 antagonist in the treatment of IL-23 mediated diseases.

• patent2020/09/16

  Korean Intellectual Property Office Granted AskAt a Use Patent of COX-2 Inhibitor (AAT-076) for Ocular Diseases

  AskAt Inc. announced today that AskAt received a notice of allowance dated September 9, 2020 from the Korean Intellectual Property Office in connection with the Application No. 10-2015-7027114, a use patent of COX-2 inhibitor (AAT-076) for ocular diseases.

• patent2020/09/09

  MPTO Grants AskAt a Patent for the Use of EP4 Receptor Antagonists in the Treatment of Nash-Associated Liver Cancer

  AskAt received a Notice of Allowance issued on August 17, 2020 from the Mexican　Patent and Trademark Office (MPTO) in connection with Application No.MX/a/2018/005715, a use patent for AskAt’s EP4 receptor antagonists in the treatment of NASH-associated liver cancer.

• patent2020/07/29

  Brazilian National Institute of Industrial Property Grants AskAt’s EP4 Antagonist Cancer Use Patent

  AskAt Inc. (AskAt) received a notice of allowance dated July 21, 2020 from the
  Brazilian National Institute of Industrial Property (NIIP) in connection with
  Application No. PI1014174-0, a use patent for AskAt’s EP4 antagonists in the
  treatment of epithelial cancers.
  

• patent2020/07/10

  National Institute of Industrial Property (Instituto Nacional da Propriedade Industrial: INPI) Approves Substance Patent for AskAt’s EP4 antagonist (AAT- 008) In Brazil

  AskAt Inc. received that allowance of a substance patent for its EP4 receptor antagonist (AAT-008), Application No. PI0414130-0 was published in Brazilian Industrial Property Journal (Official Gazette) No: 2582 of June 30, 2020.

• patent2020/06/22

  Galliprant® Granted Supplementary Protection Certificate (SPC) in Poland

  Poland granted SPC for Galliprant® on May 6, 2020, a veterinary drug product developed and marketed by Elanco Animal Health Inc. (Elanco). The SPC extends the period of exclusive sales rights for Galliprant® until March 1, 2031. Additional SPCs for Galliprant® are currently under examination in several major EU countries. The grant in Poland marks the eighth approval in the EU, following grants received in Italy, Holland, Spain, Germany, France, Ireland, and Greece.
  

• patent2020/06/19

  Galliprant® Granted Supplementary Protection Certificate (SPC) in Greece

  Greece granted SPC for Galliprant® on February 24, 2020, a veterinary drug product developed and marketed by Elanco Animal Health Inc. (Elanco). The SPC extends the period of exclusive sales rights for Galliprant® until March 2, 2031. Additional SPCs for Galliprant® are currently under examination in several major EU countries. The grant in Greece marks the seventh approval in the EU, following grants received in Italy, Holland, Spain, Germany, France, and Ireland.

• business2020/04/07

  Galliprant Receives Market Authorization in Japan

  Elanco Japan, a division of Elanco Animal Health (Headquarters: Indiana,USA), announced that it received marketing authorization on April 3, 2020 for Galliprant （Galliprant® / grapiprant / AAT-007 / RQ-00000007）for the treatmentof canine osteoarthritis from the Ministry of Agriculture, Forestry and Fisheries.
  
  Galliprant was launched in the U.S. and EU on January 2017 and April 2019, respectively, and has become a major therapeutic in the treatment of this condition. Galliprant was named Best Companion Animal Product in the U.S. in 2017.

• ir2020/03/30

  7th period financial statement release

• patent2020/03/25

  Autoimmune disease Use Patent for EP4 antagonist Approved in Canada

  AskAt received a Notice of Allowance dated February 11, 2020 from the Canadian Intellectual Property Office (CIPO) in connection with the Application No. 2,789,665, a use patent of EP4 antagonist for the treatment of IL-23 mediated diseases.

• science2020/03/11

  AskAt Review Article Presenting EP4 Antagonist’s Mechanism of Action in Cancer Immunotherapy Published in Leading Scientific Journal

  Frontiers in Immunology, an international scientific journal focusing on immunology, cancer immunity and immunotherapy, has published AskAt’s review article describing a mechanism of anti-tumor action of the EP4 antagonist. The review is based on immuno-oncological evidence recently published in scientific journals. It suggests a new concept for the mechanism of action of the EP4 antagonist, in combination with a cancer-immunity cycle theory, demonstrating a position for the therapy within current cancer immunotherapy. This new concept helps to advance understanding of AskAt’s EP4 antagonists, AAT-007 and AAT-008, in cancer immunotherapy, and provides an immunological background of EP4 antagonist therapy in combination with immune checkpoint inhibitors, chemotherapy, and tumor radiotherapy. Currently, AAT-007 and AAT-008 are being developed in the U.S. and China, initially targeting colorectal cancer and non-small cell lung cancer.
  

• patent2020/03/03

  Mexican Institute of Industrial Property Grants AskAt a Use Patent of its EP4 Receptor Antagonist for the Treatment of Cartilage Disease

  AskAt received a notice of allowance dated February 6, 2020 for a use patent of its EP4 receptor antagonist for the treatment of cartilage disease. The notice was issued in connection with Mexican Patent Application No. MX/a/2015/013328, from the Mexican Institute of Industrial Property (IMPI: Instituto Mexicano de la Propiedad Industrial).

• patent2020/02/14

  Rospatent Grants AskAt a Patent for the Use of EP4 Receptor Antagonists in the Treatment of Nash-Associated Liver Cancer

  AskAt received an Official Decision of Grant issued on January 20, 2020 from the Russian Federal Service for Intellectual Property, Patents and Trademarks (Rospatent) in connection with Application No. 2018117891, a use patent for AskAt’s EP4 receptor antagonists in the treatment of NASH-associated liver cancer.

• patent2020/02/03

  Mexican Institute of Industrial Property Grants AskAt a Formulation Patent for its COX-2 Inhibitor (AAT-076)

  AskAt received a notice of allowance dated January 22, 2020 from the Mexican Institute of Industrial Property (IMPI: Instituto Mexicano de la Propiedad Industrial) in connection with the Company's Mexican Patent Application No. MX/a/2014/004566, a formulation patent for its COX-2 inhibitor (AAT-076).

• patent2020/01/30

  USPTO Grants Expansion of AskAt’s EP4 Antagonist Cancer Use Patent

  AskAt Inc. (AskAt) received a Notice of Allowance dated January 21, 2020 from the United States Patent and Trademark Office (USPTO) in connection with Application No. 15/602,686, a use patent for AskAt’s EP4 antagonist AAT-007 in the treatment of epithelial cancers. AskAt previously received an allowance for the use of AAT-007 in the treatment of gastric, lung, prostate, colon, and breast cancers. The current allowance significantly expands the use of AAT-007, covering most tumors that occur in a variety of tissues and organs.
  Clinical Development of AskAt’s EP4 Antagonists for Cancer Immunotherapy
  Ikena Oncology (formally Kyn Therapeutics, a parent company of Arrys Therapeutics, which licensed worldwide rights to AskAt’s EP4 antagonists except in China) and Ningbo NewBay Pharmaceutical Co. Ltd. (a subsidiary of Ningbo Tai Kang Medical Technology Co. Ltd., which licensed AskAt’s EP4 antagonists for cancer use in China), are currently conducting clinical studies of grapiprant (IK-007/RMX-1002) in the U.S. and China, respectively.

• patent2020/01/24

  Galliprant® Granted Supplementary Protection Certificate (SPC) in Ireland

  Ireland granted SPC for Galliprant® on December 17, 2019, a veterinary drug product developed and marketed by Elanco Animal Health Inc. (Elanco). The SPC extends the period of exclusive sales rights for Galliprant® until February 28, 2031. Additional SPCs for Galliprant® are currently under examination in several major EU countries. The grant in Ireland marks the sixth approval in the EU, following grants received in Italy, Holland, Spain, Germany, and France.
  

• patent2020/01/23

  USPTO Grants AskAt a Patent for the Use of EP4 Receptor Antagonists in the Treatment of Nash-Associated Liver Cancer

  AskAt received a Notice of Allowance dated January 14, 2020 from the United States Patent and Trademark Office (USPTO) in connection with Application No. 16/417,870, a use patent for AskAt’s EP4 receptor antagonists in the treatment of NASH-associated liver cancer.